optical sensor arrays

The in vitro diagnostic company said it would use the financing to commercialize its antibiotic susceptibility platform called Reveal. 

The partners believe their technology could have advantages over others used in early-stage cancer detection, such as next-generation sequencing.

The company will work with the nonprofit to create a test for resource-poor settings. It is also working under a new NIH grant to add antibiotic susceptibility testing to its system.